KNSA — Kiniksa Pharmaceuticals Ltd · P/E 53, rev $677.6M

Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.

Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.

Use this KNSA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KNSA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KNSA SEC filings page. Lician reads the product cache first so this HTML stays unique to Kiniksa Pharmaceuticals Ltd even when a live quote feed is slow.

Kiniksa Pharmaceuticals Ltd latest statements (FY2025)

Latest cached year on this hub. Full KNSA income, balance, and cash tables.

  • Revenue$677.6M
  • Net Income$59.0M
  • Total Assets$763.6M
  • Total Debt$0
  • Free Cash Flow$136.4M

KNSA recent filings